

Showcasing the battle of antimicrobial peptides against resistant bacteria in the fight against antimicrobial resistance by James Flynn and Dr Sarah Hudson at the Bernal Institute, University of Limerick, Ireland.

Tuning the strength and swelling of an injectable polysaccharide hydrogel and the subsequent release of a broad spectrum bacteriocin, nisin A

A balance of glycol chitosan and crosslink density controls the release of a bacteriocin from injectable hydrogels, modulating swelling and mechanical properties without sacrificing physiologically appropriate conditions for antimicrobial peptides.

### As featured in:



See Sarah P. Hudson et al.,  
*J. Mater. Chem. B*, 2020, **8**, 4029.



Cite this: *J. Mater. Chem. B*, 2020, 8, 4029

## Tuning the strength and swelling of an injectable polysaccharide hydrogel and the subsequent release of a broad spectrum bacteriocin, nisin A†

James Flynn,<sup>a</sup> Edel Durack,<sup>a</sup> Maurice N. Collins  <sup>b</sup> and Sarah P. Hudson  <sup>a\*</sup>

Bacteriocins, which are antimicrobial peptides, are a potential alternative to current ineffective antimicrobial therapies. They can inhibit the growth of clinically relevant pathogens but their proteinaceous nature renders them susceptible to degradation and deactivation *in vivo*. We have designed injectable polysaccharide hydrogels for the controlled release of an incorporated bacteriocin, nisin. Nisin was encapsulated into these hydrogels which were composed of varying percentages of oxidised dextran, alginate functionalised with hydrazine groups and glycol chitosan. The nisin gels exhibited antimicrobial activity against *Staphylococcus aureus* up to 10 days. The incorporation of a deacetylated chitosan and the reduction of alginate-hydrazine could be used to tune the gel's swelling behaviour, strength and the subsequent release profile of nisin. Glycol chitosan also shows synergistic inhibition of *S. aureus* with nisin.

Received 17th January 2020,  
Accepted 12th March 2020

DOI: 10.1039/d0tb00169d

[rsc.li/materials-b](http://rsc.li/materials-b)

## 1 Introduction

Antimicrobial resistant infections pose an urgent threat to public health, and although antimicrobial resistance is a natural phenomenon, cases have been fueled by the overuse or misuse of antimicrobial agents, thus exposing pathogens to sub-inhibitory levels of antibiotics, inducing resistance.<sup>1</sup> A prevalence of resistant cases in strains of *Streptococcus pneumoniae*, methicillin resistant *Staphylococcus aureus* (MRSA), *Mycobacterium tuberculosis* (TB), *Acinetobacter*, *Enterococci* and multi drug resistant Gram-negative bacteria have resulted in the reduced efficacy of certain antimicrobial therapies – rendering patients, particularly those who are immunocompromised, susceptible to life-threatening infections.<sup>2</sup> In order to replace these ineffective antimicrobial therapeutics, novel antimicrobial agents are required to combat the ever-increasing rates of antimicrobial resistance in pathogenic bacteria.<sup>2</sup> According to the 2017 world surveillance report by the WHO, there are few new classes of antibiotics in the clinical pipeline against drug resistant clinical pathogens.<sup>3</sup>

One class of antimicrobial that have shown promising inhibitory activity against pathogenic bacteria, are bacteriocins.<sup>4–7</sup>

Bacteriocins are peptides that exhibit an antimicrobial effect. They are produced by bacteria to inhibit competing bacteria. A number of bacteriocins have been identified to date, with inhibitory effects toward clinically relevant Gram positive and Gram negative bacteria, including strains that have shown resistance to other drug treatments, such as *S. aureus*, *S. pneumonia*, *Clostridium difficile*, vancomycin resistant enterococci and various mycobacteria.<sup>8–10</sup> While bacteriocins show potential for therapeutic application, they exhibit a range of issues *in vivo* such as degradation by proteolytic enzymes, poor solubility and aggregation and unfolding during both formulation and storage.<sup>11</sup> Nisin A, a 3.4 kDa peptide, is a bacteriocin produced by the Gram positive lactic acid bacterium (LAB) *Lactococcus lactis* subsp. *lactis*. The presence of lanthionine rings in its structure classifies nisin A as a lantibiotic. Nisin A has FDA approval for use as a food additive (E234) and is a certified GRAS excipient and shows potential for clinical application. Inhibitory activity has been demonstrated against pathogenic bacterial species including *S. aureus*, *E. coli*, *S. pneumoniae*, *E. faecium* and *C. difficile*.<sup>12–14</sup> Nisin A, in addition to exhibiting antimicrobial properties also exhibits immunomodulatory and anticancer activity.<sup>15–17</sup> However, the susceptibility of nisin A to degradation by the intestinal digestive enzymes trypsin and  $\alpha$ -chymotrypsin has hindered the development of this bacteriocin as an antimicrobial therapeutic, thus no FDA approved clinical dosage form of this antimicrobial exists.<sup>18–24</sup>

Hydrogels prepared from natural biomaterials exhibit high biocompatibility, biodegradability and resemble the extracellular

<sup>a</sup> Department of Chemical Sciences, SSPC, SFI Research Centre for Pharmaceuticals, Bernal Institute, University of Limerick, Co., Limerick, Ireland.

E-mail: [sarah.hudson@ul.ie](mailto:sarah.hudson@ul.ie)

<sup>b</sup> Bernal Institute, School of Engineering, University of Limerick, Co., Limerick, Ireland

† Electronic supplementary information (ESI) available: The methods and results of the gel permeation chromatography analysis of the as-received and functionalized polymers, the degree of aldehyde substitution of the dextran and scanning electron micrographs of formed hydrogels. See DOI: [10.1039/d0tb00169d](https://doi.org/10.1039/d0tb00169d)

matrix (ECM).<sup>25,26</sup> These natural biomaterials – namely dextran, chitosan, collagen, alginate, fibrin, elastin and hyaluronic acid have been extensively researched for their potential use in many different applications,<sup>27–29</sup> from drug delivery to cell therapies.<sup>30,31</sup> *In situ* forming hydrogels offer a range of advantages such as tunable properties and local administration.<sup>32</sup> *In situ* cross-linking can be generated by either chemical or physicochemical association factors such as ion induced or thermally induced gelling.<sup>30</sup> In this work, an injectable hydrogel, composed of dextran, alginate and glycol chitosan (GC), has been designed with tunable swelling and mechanical properties. The release of an incorporated bacteriocin, nisin, is subsequently controlled, with potential synergistic antimicrobial activity with the GC.

Dextrans are natural polysaccharides of glucose, with  $\alpha$ -1,6 linkages and hydroxylated cyclohexyl units. They exhibit biocompatibility and biodegradability in the blood and in the gastrointestinal tract making them attractive materials for the delivery of drugs *in vivo*.<sup>33–35</sup> Dextran can be cross-linked with divalent metal cations, and acid chlorides with UV induced gelation,<sup>36,37</sup> functionalized with sodium periodate to dextran-dialdehyde, or by direct addition of glutaraldehyde with  $MgCl_2$ .<sup>38–40</sup> Alginate is typically utilized *via* crosslinking with multivalent cations such as  $Ca^{2+}$  or  $Ba^{2+}$ , through interactions with carboxylic groups present in its structure, thus forming a gel network.<sup>41,42</sup> These crosslinking methods however, possess drawbacks such as poor gel stability at neutral pH's, the need for induced polymerization with UV, and poor structural homogeneity caused by uncontrolled crosslinking with  $Ca^{2+}$ , all of which limit their clinical application.<sup>43</sup>

Schiff base or hydrazone bond formation, has been utilized to produce polysaccharide based cross-linked hydrogels as this mode of crosslinking allows for variabilities in the microstructure of the gels by altering the hydrogel parameters.<sup>44,45</sup> Hudson *et al.* developed an injectable dextran-aldehyde and carboxymethyl-cellulose-hydrazine hydrogel for the delivery of amphotericin B. They conjugated the amphotericin B to the dextran and injected the formulation. Conjugating the drug to the dextran allowed for antifungal drug release, killing *Candida albicans* for up to 3 weeks. The release profile was varied by changing the degree of functionalization of the dextran-aldehyde.<sup>33</sup> Sharma and Taneja *et al.* investigated hydrazone link based xanthan-PEG gels for controlled drug delivery of doxorubicin and 3D cell culture. Xanthan was oxidized with sodium periodate, and the PEG was functionalized with hydrazine groups allowing for an injectable administration.<sup>46</sup>

Chitosan has been shown to exhibit antimicrobial activity both independently and synergistically, and is labelled as an anti-bacterial biopolymer.<sup>47</sup> However, its poor solubility presents a hindrance in its application.<sup>48,49</sup> In this manuscript, the addition of a deacetylated chitosan, glycol chitosan, was used as it is water soluble and capable of controlling the release of a cationic anti-microbial peptide, nisin A, from an injectable dextran-dialdehyde and alginate-hydrazine hydrogel. Controlling the swelling, mechanical properties and inhibitory activity of an antimicrobial peptide (AMP) loaded hydrogel has not been achieved previously through the use of glycol chitosan.

## 2 Experimental

### 2.1 Materials

Nisin A (95%, isolated from *Lactococcus lactis* in sauerkraut) was obtained from Handary, Belgium. Dextran (from *Leuconostoc mesenteroides*, 100–200 kDa), alginic acid (from brown algae, low viscosity), sodium (meta) periodate (>99%), ethylene glycol (99%), *N*-hydroxysulfosuccinimide sodium salt (S-NHS, > 98%), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC, crystalline), adipic acid dihydrazide (>98%), hydroxylamine hydrochloride, glycol chitosan (>60%), trifluoroacetic acid (TFA, >99%), acetonitrile (ACN, >99.9%) and phosphate buffered saline (PBS) were all purchased from Sigma Aldrich, Ireland. Dimethyl sulfoxide (DMSO) was purchased from VWR International. Liquid nitrogen was supplied by BOC Gases (Ireland). Sodium taurocholate (>95%), L- $\alpha$ -lecithin (>99%), sodium chloride hexahydrate (98%), potassium chloride (99%), hydrochloric acid (37%, fuming) were all purchased from Fisher Scientific, Ireland. Pullulan/Dextran standards for Light Scattering/Tetra Detection (TDS3030) were provided by Particular Sciences, Dublin, Ireland. *Staphylococcus aureus* (DSM 20231) was purchased from the Leibniz Institute DSMZ – German collection of Microorganisms and Cell Cultures.

**2.2.1 Functionalization of dextran.** Dextran was oxidized to yield aldehyde groups as reported by Hudson *et al.*<sup>33</sup> A 1% w/v dextran solution was prepared in DI water. An aqueous suspension of sodium periodate (16% w/v) was added to the dextran solution slowly while stirring vigorously. The solution was allowed to stir for 2 hours in the dark. After the 2 hour period, ethylene glycol was added to stop the reaction (0.27% v/v). The solution was allowed to stir for an additional hour, after which it was dialyzed against a 3.5 kDa molecular weight cut off (MWCO) cellulose membrane in 5 l DI water with 6 water changes over 3 days, followed by freeze drying. The oxidized dextran is referred to as Dextran-CHO.

**2.2.2 Functionalization of alginic acid.** A solution of alginic acid was prepared in DI water (1% w/v) by dissolving 500 mg alginic acid in 50 ml water, and stirred for 1 hour to dissolve fully. Meanwhile, 152 mg S-NHS and 134 mg EDC were dissolved in 2 ml DMSO (50%), each. ADH was added (3.96% w/v) to the alginate solution and the pH was adjusted to 6.8 with 1 M NaOH. The EDC and S-NHS solutions were added, and the solution was allowed to stir for 6–8 hours, with the pH being constantly adjusted to 6.8 as necessary. The solution was dialyzed against 10 kDa MWCO cellulose membrane in 5 l DI water with 6 water changes over 3 days and freeze dried.

### 2.2.3 Formation of blank and nisin loaded Dex-Alg Gels

**Nisin hydrogels with no glycol chitosan.** Following a similar method to Hudson *et al.*,<sup>33</sup> hydrogels were prepared using a double barreled syringe set up. Dextran-dialdehyde was dissolved in KCl/HCl buffer (pH 2) at a concentration of 6% w/v. Alginate-hydrazine was dissolved in PBS (pH 7.4) at a concentration of 3% w/v. Both solutions were added to 1 ml syringes which were attached to a double barrel syringe apparatus. The solutions were extruded through a 21-gauge needle into a mold (6 mm  $\times$  3 mm, 100  $\mu$ l) gelation occurring *in situ* within 5–10 seconds at ambient room temperature ( $\sim$  23 °C). For hydrogels containing nisin,

the dextran-dialdehyde was dissolved in a 20 mg ml<sup>-1</sup> nisin solution (KCl/HCl, pH 2) such that each gel had a nisin concentration of approximately 1 mg.

**Nisin hydrogels with glycol chitosan.** Hydrogels with glycol chitosan were prepared as above, with the addition of glycol chitosan to the alginate solution at concentrations of 3% and 6% w/v, reducing the concentration of alginate from 3% to 1% and 0.5%, respectively. Gels containing glycol chitosan are denoted as Dex-Alg<sub>α%</sub>-GC<sub>β%</sub>, where 'α%' represents the w/v% of alginate-hydrazine and 'β%' represents the w/v% of glycol chitosan. 'Dex-Alg-GC gels' refers to the Dex-Alg<sub>3%</sub>-GC<sub>0%</sub>, Dex-Alg<sub>1%</sub>-GC<sub>3%</sub> and Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub> gels collectively, Table 1.

**2.2.4 Characterization of hydrogels.** Modified fasted state simulated gastric fluid (m-FaSSGF) was prepared by combining 36 ml 1 M sodium chloride (NaCl), 40 ml 0.001 M sodium taurocholate (NaTc), 12.5 ml 1 M HCl and 2 ml 0.005 M L- $\alpha$ -lecithin. The solution was prepared to 500 ml with DI H<sub>2</sub>O and the pH was confirmed to be 1.6.<sup>50-52</sup>

The swelling of the gels was studied by placing the pre-formed gels into a 24 well assay plate, 1 ml of m-FaSSGF (pH 1.6) was subsequently added. The plate was incubated at 37 °C and at specified time points the gels were removed with a spatula, blotted dry with filter paper and weighed. The diameter of the gels was also measured at each time point using a Vernier calipers. At each time point the buffer was totally replenished.

Mechanical characterization of the Dex-Alg-GC gels both with and without nisin was carried out using a compression test. Gels were formed, the surface area was determined and a pressure of 100 kPa was applied (relative to the area of each sample), at a speed of 0.25  $\mu$ m min<sup>-1</sup>. The Young's modulus was determined based on the stress strain curve generated from the compression data.

**2.2.5 HPLC analysis of nisin A.** Reverse phase high performance liquid chromatography (RP-HPLC) was used to quantitatively analyze nisin A following a previously described method.<sup>52</sup> Analytical RP-HPLC was carried out on an Agilent 1260 Infinity system with UV-vis detection at 214 nm, coupled with a Gemini 00G-4435-E0 C<sub>18</sub> Phenomenex column (25 cm  $\times$  4.6 mm  $\times$  5  $\mu$ m). The mobile phase consisted of 0.1% trifluoroacetic acid (TFA) (buffer A) and acetonitrile (ACN) with 0.1% TFA (buffer B) using a gradient of 75:25 to 55:45 (A/B) over 52 minutes. The chromatogram for nisin A contained three peaks which accounted for the three components of nisin which were characterized in a previous study<sup>52</sup> and the intact nisin peak was used to quantify nisin release.

**Table 1** The composition of the various concentrations of polymer in the hydrogel constructs. The gel name indicates the %w/v glycol chitosan concentration

Gel	Dextran-dialdehyde [mg ml <sup>-1</sup> ]	Alginate-hydrazine [mg ml <sup>-1</sup> ]	Glycol chitosan [mg ml <sup>-1</sup> ]	Nisin (per gel)
Dex-Alg <sub>3%</sub> -GC <sub>0%</sub>	60	30	0	1 mg
Dex-Alg <sub>1%</sub> -GC <sub>3%</sub>		10	30	
Dex-Alg <sub>0.5%</sub> -GC <sub>6%</sub>		5	60	
Dex-GC <sub>6%</sub>		0	60	
Dex-Alg <sub>0.5%</sub>		5	0	

**2.2.6 In vitro release kinetics.** Gels were submerged in 1 ml of m-FaSSGF in a 24 well plate and incubated at 37 °C. Samples of the release media were taken at regular time points over a 30 day period, the wells were totally replenished with fresh m-FaSSGF at each time point to maintain sink conditions. Nisin presence in release media was quantified using RP-HPLC (2.2.6). All samples were filtered through a 0.22  $\mu$ m PES syringe filter prior to analysis.

#### 2.2.7 In vitro antimicrobial testing

**IC<sub>50</sub> of nisin A against *S. aureus*.** The inhibitory concentration at 50% for nisin against *S. aureus* (DSM 20231) was determined as reported in a previous study.<sup>52</sup> Briefly, a 1 mg ml<sup>-1</sup> nisin solution (KCl/HCl) was diluted with PBS to concentrations of 10, 12, 15 and 20  $\mu$ g ml<sup>-1</sup> in the wells of a 96 well plate. 150  $\mu$ l of an overnight *S. aureus* culture (OD<sub>595</sub> 0.1) was added to each test well. The plate was incubated for 24 hours at 37 °C in a Biotek Elx808 Ultra Microplate reader (Mason Technologies, Dublin, Ireland) with readings taken at 595 nm every 30 minutes.

**Synergistic activity of glycol chitosan and nisin A.** An overnight culture of *S. aureus* was cultured in BHI broth at 37 °C shaking at 140 rpm. Sterile BSA (10%, PBS pH 7.4) was added to the wells of a sterile 96 well plate (200  $\mu$ l) and incubated at 37 °C for 30 minutes. The BSA was removed and the wells were rinsed with sterile PBS. The culture was diluted to an OD<sub>595</sub> of 0.1. A 1 mg ml<sup>-1</sup> nisin solution (KCl/HCl, pH 2) was filter sterilized through a 0.22  $\mu$ m PES syringe filter. 3% and 6% GC solutions were prepared under sterile conditions, whereby GC was weighed out and UV irradiated for 30 minutes before being dissolved in sterile PBS. Dilutions were prepared at concentrations of 15  $\mu$ g nisin combined with 0, 3 and 6% GC in the wells of the 96 well plate, whereby a volume of a 1 mg ml<sup>-1</sup> nisin solution (KCl/HCl, pH 2) was added followed by the same volume of a 3%/6% GC (PBS, pH 7.4) solution to represent the ratio of nisin and dextran-CHO and GC in the gel formulation. 150  $\mu$ l of the diluted culture was added to the wells. Buffer controls (KCl/HCl), blank controls (BHI) and positive controls (*S. aureus*) were run in conjunction. The plate was incubated for 24 hours at 37 °C in a Biotek Elx808 Ultra Microplate reader (Mason Technologies, Dublin, Ireland) with readings taken at 595 nm every 30 minutes. Blank readings were subtracted from test readings.

**Antimicrobial activity of gels.** Hydrogels were prepared as previously mentioned. The gels were frozen, thawed and UV irradiated for 30 minutes. The bioactivity study was carried out in a similar way to the release study (Section 2.2.6), whereby m-FaSSGF was filter sterilized through a 0.22  $\mu$ m PES filter. Each sterile gel was administered into 1 ml of the sterile m-FaSSGF ( $n = 3$ ) in a 24 well sterile culture plate. The plate was sealed and incubated at 37 °C. After 24 hours, the FaSSGF was removed from each gel sample under sterile conditions and frozen, the media was fully replenished and removed again at day 1, 3, 5 and day 10. Controls of m-FaSSGF and blank gels were also conducted. Optical density measurements were taken every 30 minutes for 24 hours, whereby 66.7  $\mu$ l of each sample was added to 133  $\mu$ l of the same *S. aureus* culture at an OD<sub>595</sub> 0.1, in the wells of a 96 well sterile

culture plate. The plate was incubated at 37 °C in a Biotek ELx808 Ultra microplate reader (Mason Technologies, Dublin, Ireland) for 24 hours. Aliquots of the release media were kept under sterile conditions at all times. The test samples were not filtered before testing their antimicrobial activity.

**2.2.8 Biocompatibility of degradation products with HEK293 cells using *in vitro* cell assay.** MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium) assays were carried out on mammalian human embryonic kidney cells (HEK293). This assay was used to ascertain the biocompatibility of the gels containing the highest concentration of glycol chitosan within the gel formulation after a period of 14 days in FaSSGF. Cells of passages below 30 were cultured and maintained in DMEM media supplemented with 10% FBS, 1% penicillin/streptomycin and 1% L-glutamine. Cells were incubated at 37 °C, 5% CO<sub>2</sub> and 95% relative humidity. 10 000 cells were seeded per well of a 96 well assay plate, for 24 h to ensure adherence of HEK293 cells. Samples from day 14 of the stability study (Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub>) were UV treated for 30 minutes to ensure sterility. Media was changed in the wells prior to addition of the samples (10 µl). Live controls, dead controls (10% Triton X) and buffer controls (m-FaSSGF) were set up in conjunction. After an incubation period of 24 hours MTT reagent was added to each test well (10 µl). After 4 h, 100 µl propan-2-ol with 0.04 M HCl was added to each well to dissolve crystals as per manufacturers instruction. The plate was shaken and read at 570 nm. Test results were expressed as % cells that were viable after treatment when compared with the live controls.

### 3 Results

#### 3.1 Characterization of hydrogels

**3.1.1 Hydrogel formation.** The formation of hydrogels was tested with a range of alginate-ADH and GC concentrations. Initially 60 mg ml<sup>-1</sup> dextran-CHO was combined with 40 mg ml<sup>-1</sup> alginate-ADH, which was too viscous for extrusion through the attached 21 G needle. As such the concentration of alginate-ADH was reduced to 30 mg ml<sup>-1</sup>. Upon addition of GC, it was found that the concentration of alginate-ADH must be reduced further for an appropriate viscosity for injection and thus the alginate-ADH concentration was reduced from 30% to 10% and 5% for the 3% and 6% GC gels, respectively, as shown in Table 1. It was found that in the absence of GC, in gels with a combination of 60% dextran-CHO and 5% alginate-ADH, gels did not form, while with 6% GC and 60% dextran-CHO gels formed with and without nisin present at 1 mg per gel.

**3.1.2 Mechanical characterization.** Mechanical testing of the hydrogels indicated that gels with increasing concentrations of glycol chitosan exhibited higher elastic modulus ( $E$ ) values. The modulus for the Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub> gel was found to be 37.3 ± 13.5 kPa, based on the stress-strain curve obtained. The modulus of the Dex-Alg<sub>1%</sub>-GC<sub>3%</sub> gels in comparison was lower at 19.8 ± 8.6 kPa, with the Dex-Alg<sub>3%</sub>-GC<sub>0%</sub> gels exhibiting a considerably lower modulus of 0.183 ± 0.03 kPa, Fig. 1. As the gels are compressed the macro-pores present in the gel matrix collapse allowing for deformation with little stress,




Fig. 1 Young's moduli obtained for the Dex-Alg-GC and Dex-GC gels.

while subsequently the bulk material begins to compress.<sup>53</sup> Gels containing 0, 3 and 6% GC with and without nisin (1 mg) were tested. The gels were tested after being made and after undergoing one freeze thaw cycle. The inclusion of nisin in the gels did not change the Young's modulus of the gels. Importantly, gels containing no alginate-hydrazine (Dex-GC<sub>6%</sub>) exhibited a considerably lower modulus of 2.9 ± 0.6 kPa in comparison to the gels that incorporated alginate-hydrazine (Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub>), demonstrating that while the increased concentration of GC improves the mechanical properties of the gel, alginate-hydrazine and the subsequent presence of hydrazone bonds provide structural support as expected.

**3.1.3 Swelling.** The swelling of the gels (Fig. 2) was studied in FaSSGF with a pH of 1.6 at 37 °C. The assay was carried out for just over three weeks, Table 2.

The swelling of the gels indicates that the substitution of alginate-hydrazine with GC increased the swelling behaviour of the gels, and reduced the length of time for the gels to disintegrate presumably via chain scission resulting from hydrolysis. When no GC was present (Dex-Alg<sub>3%</sub>-GC<sub>0%</sub>), no swelling was evident, however the gels did not appear to disintegrate even after 3 weeks of testing, as shown in Fig. 2. Upon introduction of GC, gels swelled to more than twice their original mass, and increased in





Fig. 2 The swelling of the gels in m-FaSSGF (pH 1.6, 37 °C) was monitored until the gels disintegrated at which point the study was stopped (y axis error bars are included).

**Table 2** The stability of the gels in m-FaSSGF at 37 °C, showing the time taken for the different formulations to disintegrate

Hydrogel	Nisin [µg per gel]	Days to disintegration	Max. swell [%]	Max. diameter increase [%]
Dex-Alg <sub>3%</sub> -GC <sub>0%</sub>	1000	> 22 days	0	~107
Dex-Alg <sub>1%</sub> -GC <sub>3%</sub>	1000	~14 days	~200	~133
Dex-Alg <sub>0.5%</sub> -GC <sub>6%</sub>	1000	~8 days	~252	~172
Dex-GC <sub>6%</sub>	1000	~4–5 days	~180	~56
Dex-Alg <sub>0.5%</sub>	No gel formed			
Dex-GC <sub>6%</sub> -blank	0	1 day	~187	~154




**Fig. 3** The change in diameter of the hydrogel for the duration of their swelling study in m-FaSSGF (pH 1.6, 37 °C).

diameter as GC concentrations increased, Fig. 3. The higher influx from the reduced degree of cross-linking however led to gels with higher GC concentrations disintegrating faster, as shown in Table 2 and Fig. 2. Gels with no alginate present (Dex-GC<sub>6%</sub>) disintegrated after just one week, and when nisin was not incorporated they disintegrated after 1 day, indicating a stabilisation effect through nisin interactions within the gel. Dex-Alg<sub>0.5%</sub> did not form gels.

### 3.2 In vitro release of nisin

*In vitro* release studies show that increasing the concentration of GC slows the rate of nisin released into m-FaSSGF (pH 1.6, 37 °C), Fig. 4. m-FaSSGF was used as the release media as nisin exhibits a high degree of solubility in this media. The lower



**Fig. 4** Cumulative release of nisin from the Dex-Alg-GC gels into m-FaSSGF (pH 1.6) over 12 days, before disintegration of the gels.


crosslink densities, and the replacement of stiffer alginate with more flexible GC chains, (see ESI† for characterisation of as received and functionalised polymers), allows nisin to interact with the gel more readily, while increasing the length of its diffusion path out of the gel. In gels with no GC, nisin was forced to the outer perimeters of the gel allowing for a faster release. Filtering for RP-HPLC analysis meant that any nisin bound to polymer fragments were filtered out before analysis. Thus the release results may not quantitatively represent the true nisin release from the gels, and 100% release was not observed.

### 3.3 In vitro antimicrobial activity

**3.3.1 Synergistic effect of nisin A and glycol chitosan against *S. aureus*.** The m-IC<sub>50</sub> of nisin against *S. aureus* (DSM 20231) was found to be approximately 10 µg ml<sup>-1</sup>, as reported in a previous investigation.<sup>52</sup>

Blank Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub> gel controls, without nisin, indicated inhibition of a *S. aureus* culture, Fig. 5, whereas no such inhibition was observed with the Dex-Alg<sub>3%</sub>-GC<sub>0%</sub> gels. This indicated that the soluble GC polymer may have antimicrobial properties and therefore the activity of GC and nisin, both alone and in combination against *S. aureus* was tested. Growth curves demonstrated a synergistic inhibitory effect between glycol chitosan and nisin, Fig. 6. A nisin concentration of 15 µg ml<sup>-1</sup> was tested with both 3% and 6% GC and independently (0% GC). It was found that a combination of 15 µg ml<sup>-1</sup> nisin with 3% or 6% GC completely inhibited the growth of the culture. There was no difference in the inhibition of the culture between 3 or 6% GC indicating that 3% GC in combination with 15 µg ml<sup>-1</sup> nisin is sufficient for the inhibition of *S. aureus*. Results indicated that a final O.D. of ~0.4 for 15 µg ml<sup>-1</sup> nisin alone, indicating ~35% growth reduction, while in combination with 3% GC a final O.D. of ~0.04 was obtained, indicating a reduction in growth of ~93%, Fig. 6.

**3.3.2 Antimicrobial activity of hydrogels.** Growth curves were used to determine the antimicrobial activity of nisin loaded Dex-Alg-GC<sub>0/3/6%</sub> gels and the Dex-GC<sub>6%</sub> gels. The activity was tested on days 1, 3, 5 and 10. Growth curves demonstrated that no growth was evident on the first day of the study for all tested



**Fig. 5** Inhibitory activity of the blank Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub> gel after 14 days, against *S. aureus*.




Fig. 6 Synergistic inhibitory activity against the growth of *S. aureus* exhibited by nisin and GC, alone and combined.

formulations. By day 3, growth was evident in all formulations, with the Dex-GC<sub>6%</sub> gels exhibiting the highest degree of growth. Day 5 indicated that as the gels were disintegrating, nisin was being released and the degree of inhibition increased in the Dex-Alg-GC gels. The activity of the Dex-GC<sub>6%</sub> gels remained minimal until the gels disintegrated showing inhibition at day 10, Fig. 7.

### 3.4 Biocompatibility of hydrogel degradation products

The biocompatibility of the degradation products of the Dex-Alg-GC<sub>6%</sub> gels at day 14 was assessed with HEK293 cells. MTT results demonstrated a lack of *in vitro* cytotoxicity after 24 hours. A variety of volumes of the swelling study media was used to ensure minimal pH change in the cell culture medium and buffer controls were run alongside these samples. The highest volume (15 µl) is presented in Fig. 8. All test samples show cell proliferation whereby the concentration of cells was ~20% higher than that of the control, presumably due to the presence of the polysaccharides. By selecting the media (supernatant) of Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub> at day 14 during this assay, the HEK293 cells were exposed to the highest concentration of degraded polymers. No toxicity was observed and thus none would be expected at lower concentration of the degradation products at earlier timepoints. While the gels tested do not contain the highest concentration of alginate, they do contain the highest concentration of glycol chitosan used, which is the least studied of the polymers used in terms of toxicity.

## 4 Discussion

The principle aim of this work was to develop an injectable polysaccharide based hydrogel system to encapsulate and





Fig. 7 (a) Antimicrobial activity of Dex-Alg<sub>3%</sub>-GC<sub>0%</sub> gels on days 1, 3, 5 & 10, (b) Dex-Alg<sub>1%</sub>-GC<sub>3%</sub> on days 1, 3, 5 & 10, (c) Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub> gels on days 1, 3 & 10, (d) Dex-GC<sub>6%</sub> gels on days 1, 3, 5 & 10, all against the growth of *S. aureus*.



**Fig. 8** The biocompatibility of the Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub> gel was tested against HEK293 cells. The degradation products exhibited some proliferation of cells, but did not show any cytotoxicity.

control the release of a broad spectrum bacteriocin, nisin A. Dextran and alginate have been extensively employed in biomedical applications because of their biocompatibility, biodegradability and ease of production.<sup>54–56</sup> Injectable hydrogels and other delivery platforms such as mesoporous materials have been explored for the encapsulation and delivery of sensitive proteins and peptides in previous studies.<sup>52,56</sup> Whilst the mesoporous matrices facilitated protection of nisin against degradation by pepsin, and allowed nisin to be released into FaSSGF, retaining its antimicrobial activity, certain limitations such as difficulty in structural modification and in tuning the release/mechanical properties, alongside potential biocompatibility issues were present. Thus, innovative designs of delivery platforms that can be tailored to (1) control the release of a range of peptides and (2) tune their mechanical properties for specific applications, whilst satisfying the physicochemical conditions of the encapsulated peptide are needed.

Here, it was hypothesized that the combination of (1) decreasing the degree of crosslink density by reducing the concentration of alginate-hydrazine and (2) the addition of a more flexible polymer (GC) in an injectable dextran alginate gel would tune the degree of swelling and mechanical properties while subsequently controlling the release of nisin. By allowing nisin to permeate deeper in the pores of the hydrogel, nisin is free to interact with the 3D gel structure thus reducing the rate of release. Zhu *et al.* have previously demonstrated the ability of chitosan to form electrostatic complexes with certain biomolecules such as lysozyme and nisin.<sup>49</sup> The increase in porosity of the gels due to a reduction in covalent crosslinking (less alginate-ADH added) also allows for an increased influx of media and subsequent swelling degree. The incorporation of GC was hypothesized to increase the mechanical stiffness and the antimicrobial activity of the gels against a pathogenic strain of *S. aureus* and control the release of nisin.

Gels containing no GC with the lowest concentration of alginate-hydrazine (Dex-Alg<sub>0.5%</sub>) did not form a gel upon extrusion through a 21 G needle presumably due to the high reduction in hydrazine side groups required for cross linking. On the

other hand, gels with GC incorporated, with 30 mg ml<sup>-1</sup> alginate-hydrazine became too viscous for gel formation and as such the concentration of alginate-ADH had to be reduced with increasing GC content. Interestingly, as the concentration of GC is increased, the stiffness of the freshly made gel increases, perhaps due to a higher degree of polymer chain entanglement (more flexible chains), Fig. 1. Other studies have probed the tuning of the mechanical properties of hydrogels with particular focus on interpenetrating networks (IPN)<sup>57</sup> and varying ionic concentration. Feng *et al.* demonstrated that by varying the ionic concentration in their peptide solutions from 0.1–2.1 M, they could modulate the stiffness of the gels, as measured by small angle X-ray scattering (SAXS).<sup>58</sup> While this effect has been observed in other studies for both stiffness and swelling,<sup>59</sup> there are certain limitations posed, particularly in terms of the suitability of the gel matrix for peptides/proteins. These limitations include reduced diffusion coefficients due to salt barrier formations, as well as the increased potential for 'salting out' or aggregation of biomolecules encapsulated in the gel.<sup>58</sup> Through the alteration of the hydrogel network *via* reduction in the degree of covalent crosslinking and substitution with GC, the mechanical properties of the gels become tunable without increasing the risk of aggregation or precipitation of the encapsulated peptide. The presence of nisin in the gels did not appear to have any impact on the stiffness.

Swelling studies were conducted on the Dex-Alg-GC and Dex-GC<sub>6%</sub> gels. The reduction of covalent bonding and subsequent expansion of the gel network caused by the replacement of the hydrazine functionalized alginate by the glycol chitosan, allows for a higher solvent influx. Thus the higher % GC gels swell to a higher degree. The (1) reduction of alginate-hydrazine and (2) introduction of GC showed an increased degree of swelling potentially due to the reduction in covalent cross link densities which are replaced by physical chain entanglements.

It was hypothesized that alteration of the gel network through this reduction of covalent crosslinking would allow the nisin to diffuse further into the gels mesh, allowing nisin to interact more with the hydrogel matrix, thus slowing down its release rate. Indeed, nisin release appeared to be slowed by the introduction of increasing GC concentration and simultaneous reduction in alginate-hydrazine concentration, Fig. 4. The release was carried out over a period of two weeks for the 0% gels, 22 days for the 3% gels and 10 days for the 6% gels, after which the 3% and 6% GC gels had fully disintegrated. The respective final cumulative release detected by RP-HPLC was 70%, 62% and 27%. The release study was carried out for a more extended period than the swelling study as gels were not removed at each sampling point reducing additional stresses on the gel structures, thereby extending their stability. However, limitations due to the filtering of release samples mean that the release detected by RP-HPLC may not be indicative of the actual concentration of nisin released. As no nisin was detected in the release media after the gels had fully disintegrated, it was hypothesized that the nisin had bound to the soluble polymer fragments, and these were removed upon filtration. As such the release study was repeated under sterile conditions and the release media was tested for antimicrobial activity at days 1, 3, 5 and 10,

without the filtration step, to prevent filtering out any polymer bound nisin.

GC, a cationic derivative of chitosan, was employed in these formulations for (1) its potential interactions with dextran-CHO and alginate-hydrazine to tune its swelling and mechanical properties, (2) potential electrostatic interactions between the GC and nisin to promote interactions with the gel structure and (3) its hypothesized synergistic antimicrobial activity with nisin. GC was found to act synergistically with nisin at concentrations of 3% or 6% w/v, inhibiting a culture of *S. aureus* completely after 24 hours when combined with 15 µg nisin, Fig. 6. Blank gel (Dex-Alg-GC<sub>6%</sub> with no nisin) degradation products after 14 days were found to inhibit 50% of a *S. aureus* culture (OD 0.1) after 24 hours. He *et al.* demonstrated an *in vitro* anti-biofilm effect based on a combination of chitosan and nisin, whereby a concentration of 1% chitosan and 0.6% nisin was effective in the reduction of biofilm formation of *Shewanella putrefaciens* DHS01 and *Shewanella algae* DHS02.<sup>60</sup> Nisin has also been shown to act synergistically with compounds other than chitosan such as monoglycerides and with the lacto peroxidase system.<sup>49</sup> While the mechanism of action of chitosan as an antimicrobial still remains largely unknown, ionic interactions and subsequent membrane rupture have been hypothesized in other studies.<sup>61–63</sup>

While the antimicrobial activity of the gels did not differ greatly for the Dex-Alg-GC gels, it appeared that the Dex-GC<sub>6%</sub> gels exhibited antimicrobial activity on day 1 and after disintegration, rather than a sustained activity, Fig. 7. A common trend was observed whereby the activity decreased between days 3 and 5, and increased at day 10 where disintegration was evident in the Dex-Alg-GC gels. While a synergistic activity of inhibition was observed with solubilized nisin and GC outside of the gel system, this effect was not apparent in the gels antimicrobial activity. *In vivo* testing and a more sophisticated *in vitro* set up is required to account for this.

The Dex-Alg<sub>0.5%</sub>-GC<sub>6%</sub> gels were used to test the *in vitro* cytotoxicity of the hydrogel disintegration products in order to encompass the gel formulation with the highest concentration of GC. Alginate and dextran hydrogels have been previously shown to possess high biocompatibility.<sup>64–66</sup> The MTT assay showed that no cell death was evident, in fact cell proliferation was present. This proliferation is presumably due to the presence of polysaccharides (dextran, alginate) in the disintegration media feeding the HEK293 cells and showing an increased cell density reading. While the *in vitro* cytotoxicity testing shows biocompatibility in the assay, *in vivo* testing is essential in rendering full cytotoxicity information including site of injection as well as hemocompatibility, however the polymers used in this study have been shown in other studies to exhibit a high degree of biocompatibility *in vivo*.<sup>67–70</sup>

## 5 Conclusions

The incorporation of glycol chitosan into an injectable polysaccharide gel allows for modulation of the gels swelling and mechanical properties without sacrifice of physiologically

appropriate conditions for an encapsulated antimicrobial peptide. In previous investigations, the mechanical strength of hydrogels has been modulated through means of varying ionic concentrations, rendering the gels unsuitable for sensitive biologics. By introducing GC into these gels the mechanical strength of the gels was increased through varying GC concentrations. The incorporation of glycol chitosan also does not affect the biocompatibility, and it has been found to act synergistically with nisin in the inhibition of the growth of *S. aureus*. This study introduces a highly tuneable platform for the encapsulation and subsequent release of the AMP nisin for at least 10 days. Further development and *in vivo* testing will help define, develop, and utilise this system for a range of different clinical applications such as anti-biofilm coatings, coating for medical devices, controlled release delivery depots and for other AMP's.

## Funding

This research was funded through the help of Science Foundation Ireland grant 13/CDA/2122, SSPC, the SFI Research Centre for Pharmaceuticals (12/RC/2275\_p2) and the Department of Chemical Sciences, University of Limerick, Ireland.

## Conflicts of interest

The authors declare no conflict of interest.

## Acknowledgements

The authors would like to acknowledge the Chemical Sciences Department and the Bernal Institute, in particular James Kelly. We also appreciate the help of Dr Eric Dalton and the staff in Stokes Research Institute for the facilities provided.

## References

- WHO, 2016, DOI: [https://www.who.int/docs/default-source/searo/amr/global-antimicrobial-resistance-surveillance-system-\(glass\)-report-early-implementation-2016-2017.pdf?sfvrsn=ea19cc4a\\_2](https://www.who.int/docs/default-source/searo/amr/global-antimicrobial-resistance-surveillance-system-(glass)-report-early-implementation-2016-2017.pdf?sfvrsn=ea19cc4a_2).
- E. Tacconelli, E. Carrara, A. Savoldi, S. Harbarth, M. Mendelson, D. L. Monnet, C. Pulcini, G. Kahlmeter, J. Kluytmans, Y. Carmeli, M. Ouellette, K. Outterson, J. Patel, M. Cavalieri, E. M. Cox, C. R. Houchens, M. L. Grayson, P. Hansen, N. Singh, U. Theuretzbacher, N. Magrini, A. O. Aboderin, S. S. Al-Abri, N. Awang Jalil, N. Benzonana, S. Bhattacharya, A. J. Brink, F. R. Burkert, O. Cars, G. Cornaglia, O. J. Dyar, A. W. Friedrich, A. C. Gales, S. Gandra, C. G. Giske, D. A. Goff, H. Goossens, T. Gottlieb, M. Guzman Blanco, W. Hrynewicz, D. Kattula, T. Jinks, S. S. Kanj, L. Kerr, M.-P. Kieny, Y. S. Kim, R. S. Kozlov, J. Labarca, R. Laxminarayan, K. Leder, L. Leibovici, G. Levy-Hara, J. Littman, S. Malhotra-Kumar, V. Manchanda, L. Moja, B. Ndoye, A. Pan, D. L. Paterson, M. Paul, H. Qiu, P. Ramon-Pardo, J. Rodriguez-Baño, M. Sanguinetti, S. Sengupta, M. Sharland, M. Si-Mehand, L. L. Silver, W. Song, M. Steinbakk,

J. Thomsen, G. E. Thwaites, J. W. M. van der Meer, N. Van Kinh, S. Vega, M. V. Villegas, A. Wechsler-Fördös, H. F. L. Wertheim, E. Wesangula, N. Woodford, F. O. Yilmaz and A. Zorzet, *Lancet Infect. Dis.*, 2018, **18**, 318–327.

3 WHO, 2017, entity/medicines/areas/rational\_use/antibacterial\_agents\_clinical\_development/en/index.html.

4 H. D. Marston, D. M. Dixon, J. M. Knisely, T. N. Palmore and A. S. Fauci, *JAMA, J. Am. Med. Assoc.*, 2016, **316**, 1193–1204.

5 A. Fleming, in *Les Prix Nobel en 1945*, ed. A. Holmberg, Nobel Foundation, Stockholm, 1946.

6 E. Martens and A. L. Demain, *J. Antibiot.*, 2017, **70**, 520–526.

7 C. J. Michele, J. Langer and L. Slawomirski, *Antimicrobial Resistance in G7 Countries and Beyond: Economic Issues, Policies and Options for Action*, OECD, 2015.

8 CDC, Antibiotic Resistance Threats in the United States, 2013 | Antibiotic/Antimicrobial Resistance|CDC, 2013.

9 P. N. Malani, *JAMA, J. Am. Med. Assoc.*, 2014, **311**, 1438–1439.

10 B. B. Hui, D. M. Whiley, B. Donovan, M. G. Law and D. G. Regan, *Sex. Transm. Infect.*, 2016, **93**(3), 221–225, DOI: 10.1136/sextrans-2016-052738.

11 T. A. S. Aguirre, D. Teijeiro-Osorio, M. Rosa, I. S. Coulter, M. J. Alonso and D. J. Brayden, *Adv. Drug Delivery Rev.*, 2016, **106**, 223–241, DOI: 10.1016/j.addr.2016.02.004.

12 K. Kuwano, N. Tanaka, T. Shimizu, K. Nagatoshi, S. Nou and K. Sonomoto, *Int. J. Antimicrob. Agents*, 2005, **26**, 396–402.

13 E. Severina, A. Severin and A. Tomasz, *J. Antimicrob. Chemother.*, 1998, **41**, 341–347.

14 A. Bartoloni, A. Mantella, B. P. Goldstein, R. Dei, M. Benedetti, S. Sbaragli and F. Paradisi, *J. Chemother.*, 2004, **16**, 119–121.

15 J. M. Shin, J. W. Gwak, P. Kamarajan, J. C. Fenno, A. H. Rickard and Y. L. Kapila, *J. Appl. Microbiol.*, 2016, **120**, 1449–1465.

16 C. Aranha, S. Gupta and K. V. R. Reddy, *Contraception*, 2004, **69**, 333–338.

17 N. E. Joo, K. Ritchie, P. Kamarajan, D. Miao and Y. L. Kapila, *Cancer Med.*, 2012, **1**, 295–305.

18 C. Valenta, A. Bernkop-Schnürch and H. P. Rigler, *J. Pharm. Pharmacol.*, 1996, **48**, 988–991.

19 T. Ugurlu, M. Turkoglu, U. S. Gurer and B. G. Akarsu, *Eur. J. Pharm. Biopharm.*, 2007, **67**, 202–210.

20 A. D. van Staden, A. M. Brand and L. M. T. Dicks, *J. Appl. Microbiol.*, 2012, **112**, 831–840.

21 J. K. Dill, J. A. Auxier, K. F. Schilke and J. McGuire, *J. Colloid Interface Sci.*, 2013, **395**, 300–305.

22 K.-H. Jung, M.-W. Huh, W. Meng, J. Yuan, S. H. Hyun, J.-S. Bae, S. M. Hudson and I.-K. Kang, *J. Appl. Polym. Sci.*, 2007, **105**(5), 2816–2823, DOI: 10.1002/app.25594.

23 R. C. Correia, A. F. Jozala, K. F. Martins, T. C. V. Penna, E. A. D. R. Duek, C. D. O. Rangel-Yagui and A. M. Lopes, *World J. Microbiol. Biotechnol.*, 2015, **31**, 649–659.

24 K. Yamakami, H. Tsumori, Y. Sakurai, Y. Shimizu, K. Nagatoshi and K. Sonomoto, *Pharm. Biol.*, 2013, **51**, 267–270.

25 R. Barbucci, *Hydrogels*, Springer, Milan, Milano, 2009.

26 X. Bai, M. Gao, S. Syed, J. Zhuang, X. Xu and X.-Q. Zhang, *Bioactive Mater.*, 2018, **3**, 401–417.

27 M. Liu, X. Zeng, C. Ma, H. Yi, Z. Ali, X. Mou, S. Li, Y. Deng and N. He, *Bone Res.*, 2017, **5**, 17014.

28 F. Zamboni, S. Vieira, R. L. Reis, J. Miguel Oliveira and M. N. Collins, *Prog. Mater. Sci.*, 2018, **97**, 97–122.

29 C. A. Murphy, J. B. Costa, J. Silva-Correia, J. M. Oliveira, R. L. Reis and M. N. Collins, *Appl. Mater. Today*, 2018, **12**, 51–71.

30 D. Y. Ko, U. P. Shinde, B. Yeon and B. Jeong, *Prog. Polym. Sci.*, 2013, **38**, 672–701.

31 F. Zamboni and M. N. Collins, *Int. J. Pharm.*, 2017, **521**, 346–356.

32 E. Bakaic, N. M. B. Smeets, T. Hoare, C. R. Nuttelman, C. N. Bowman, K. S. Anseth, M. Rheinstädter, T. Hoare, X. Li and H. Chen, *RSC Adv.*, 2015, **5**, 35469–35486.

33 S. P. Hudson, R. Langer, G. R. Fink and D. S. Kohane, *Biomaterials*, 2010, **31**, 1444–1452.

34 J. Varshosaz, *Exp. Opin. Drug Delivery*, 2012, **9**, 509–523.

35 E. Markovsky, H. Baabur-Cohen, A. Eldar-Boock, L. Omer, G. Tiram, S. Ferber, P. Ofek, D. Polyak, A. Scomparin and R. Satchi-Fainaro, *J. Controlled Release*, 2012, **161**, 446–460.

36 J. D. Kosmala, D. B. Henthorn and L. Brannon-Peppas, *Biomaterials*, 2000, **21**, 2019–2023.

37 S.-H. Kim and C.-C. Chu, *J. Biomed. Mater. Res.*, 2000, **49**, 517–527.

38 A. Jeanes and C. A. Wilham, *J. Am. Chem. Soc.*, 1950, **72**, 2655–2657.

39 J. Maia, R. A. Carvalho, J. F. J. Coelho, P. N. Simões and M. H. Gil, *Polymer*, 2011, **52**, 258–265.

40 X.-B. Yuan, H. Li, X.-X. Zhu and H.-G. Woo, *J. Chem. Technol. Biotechnol.*, 2006, **81**, 746–754.

41 A. D. Augst, H. J. Kong and D. J. Mooney, *Macromol. Biosci.*, 2006, **6**, 623–633.

42 S. K. Bajpai and R. Tankhiwale, *Polym. Int.*, 2008, **57**, 57–65.

43 C. K. Kuo and P. X. Ma, *J. Biomed. Mater. Res., Part A*, 2008, **84**, 899–907.

44 J. Karvinen, T. O. Ihlainen, M. T. Calejo, I. Jönkkäri and M. Kellomäki, *Mater. Sci. Eng., C*, 2019, **94**, 1056–1066.

45 J. Karvinen, T. Joki, L. Ylä-Outinen, J. T. Koivisto, S. Narkilahti and M. Kellomäki, *React. Funct. Polym.*, 2018, **124**, 29–39.

46 P. K. Sharma, S. Taneja and Y. Singh, *ACS Appl. Mater. Interfaces*, 2018, **10**, 30936–30945.

47 T. M. Tamer, M. A. Hassan, A. M. Omer, K. Valachová, M. S. M. Eldin, M. N. Collins and L. Šoltés, *Carbohydr. Polym.*, 2017, **169**, 441–450.

48 T. Jiang, R. James, S. G. Kumbar and C. T. Laurencin, in *Natural and Synthetic Biomedical Polymers*, ed. S. G. Kumbar, C. T. Laurencin and M. Deng, Elsevier, Oxford, 2014, pp. 91–113, DOI: 10.1016/B978-0-12-396983-5.00005-3.

49 X. Zhu, H. Wu, J. Yang, J. Tong, J. Yi, Z. Hu, J. Hu, T. Wang and L. Fan, *React. Funct. Polym.*, 2015, **91**–92, 71–76.

50 M. R. C. Marques, R. Loebenberg and M. Almkainzini, *Dissolution Technol.*, 2011, **18**, 15–28.

51 P. Bannigan, K. Stokes, A. Kumar, C. Madden and S. P. Hudson, *Int. J. Pharm.*, 2018, **552**, 180–192.

52 J. Flynn, S. Mallen, E. Durack, P. M. O'Connor and S. P. Hudson, *J. Colloid Interface Sci.*, 2019, **537**, 396–406.

53 M. N. Collins and C. Birkinshaw, *J. Mater. Sci.: Mater. Med.*, 2008, **19**, 3335–3343.

54 C. J. De Groot, M. J. A. Van Luyn, W. N. E. Van Dijk-Wolthuis, J. A. Cadée, J. A. Plantinga, W. D. Otter and W. E. Hennink, *Biomaterials*, 2001, **22**, 1197–1203.

55 J. A. Cadée, M. J. A. van Luyn, L. A. Brouwer, J. A. Plantinga, P. B. van Wachem, C. J. de Groot, W. den Otter and W. E. Hennink, *J. Biomed. Mater. Res.*, 2000, **50**, 397–404.

56 M. George and T. E. Abraham, *J. Controlled Release*, 2006, **114**, 1–14.

57 J. Li and D. J. Mooney, *Nat. Rev. Mater.*, 2016, **1**, 16071.

58 Y. Feng, M. Taraban and Y. B. Yu, *Soft Matter*, 2012, **8**, 11723–11731.

59 G. Nisato, J. P. Munch and S. J. Candau, *Langmuir*, 1999, **15**, 4236–4244.

60 M. He, Q.-Y. Guo, W. Song, B.-G. Li and G.-W. Zhang, *Food Control*, 2017, **79**, 349–355.

61 E. I. Rabea, M. E. T. Badawy, C. V. Stevens, G. Smagghe and W. Steurbaut, *Biomacromolecules*, 2003, **4**, 1457–1465.

62 B. Stephen Inbaraj, T.-Y. Tsai and B.-H. Chen, *Sci. Technol. Adv. Mater.*, 2012, **13**, 015002.

63 S. J. Jeon, M. Oh, W.-S. Yeo, K. N. Galvão and K. C. Jeong, *PLoS One*, 2014, **9**, e92723.

64 X. Yang, E. Bakaic, T. Hoare and E. D. Cranston, *Biomacromolecules*, 2013, **14**, 4447–4455.

65 Z. Q. Liu, Z. Wei, X. L. Zhu, G. Y. Huang, F. Xu, J. H. Yang, Y. Osada, M. Zrínyi, J. H. Li and Y. M. Chen, *Colloids Surf., B*, 2015, **128**, 140–148.

66 M. C. Straccia, G. G. Ayala, I. Romano, A. Oliva and P. Laurienzo, *Mar. Drugs*, 2015, **13**, 2890–2908.

67 N. Artzi, N. Oliva, C. Puron, S. Shitreet, S. Artzi, A. bon Ramos, A. Groothuis, G. Sahagian and E. R. Edelman, *Nat. Mater.*, 2011, **10**, 890.

68 S. R. Van Tomme and W. E. Hennink, *Expert Rev. Med. Devices*, 2007, **4**, 147–164.

69 U. Ritz, M. Eberhardt, A. Klein, P. Frank, H. Götz, A. Hofmann, P. M. Rommens and U. Jonas, *Gels*, 2018, **4**, 63.

70 U. Rottensteiner, B. Sarker, D. Heusinger, D. Dafinova, S. N. Rath, J. P. Beier, U. Kneser, R. E. Horch, R. Detsch, A. R. Boccaccini and A. Arkudas, *Materials*, 2014, **7**, 1957–1974.